Table 4.
Baseline characteristics and inflammatory biomarkers in the endovascular coiling EC group.
| Variable | Overall | No-POP | POP | p |
|---|---|---|---|---|
| N = 429 | N = 315 | N = 114 | ||
| Age, y, mean ± SD | 55.4 ± 12.0 | 54.1 ± 11.8 | 58.8 ± 11.9 | <0.001* |
| Female, n (%) | 265 (61.8) | 201 (63.8) | 64 (56.1) | 0.183 |
| WFNS grade 4–5, n (%) | 87 (20.3) | 30 (9.5) | 57 (50.0) | <0.001* |
| mFS grade 3–4, n (%) | 325 (75.8) | 219 (69.5) | 106 (93.0) | <0.001* |
| Graeb 5–12, n (%) | 40 (9.3) | 15 (4.76) | 25 (21.9) | <0.001* |
| Acute hydrocephalus, n (%) | 180 (42.0) | 109 (34.6) | 71 (62.3) | <0.001* |
| Posterior circulation, n (%) | 77 (18.0) | 44 (14.0) | 33 (29.0) | <0.001* |
| Current smoking, n (%) | 127 (29.6) | 92 (29.2) | 35 (30.7) | 0.857 |
| Current alcohol abuse, n (%) | 104 (24.2) | 74 (23.5) | 30 (26.3) | 0.635 |
| Diabetes mellitus, n (%) | 44 (10.3) | 30 (9.5) | 14 (12.3) | 0.515 |
| Hypertension, n (%) | 273 (63.6) | 185 (58.7) | 88 (77.2) | <0.001* |
| Hyperlipidemia, n (%) | 41 (9.6) | 30 (9.5) | 11 (9.7) | >0.99 |
| Heart disease, n (%) | 40 (9.3) | 21 (6.7) | 19 (16.7) | 0.003* |
| Current use of anti-platelet aggregation drugs, n (%) | 24 (5.6) | 16 (5.1) | 8 (7.0) | 0.594 |
| White blood cell counta, median (IQR) | 12.4 (9.67–15.53) | 11.55 (9.32–14.39) | 14.94 (11.32–17.96) | <0.001* |
| Lymphocyte counta, median (IQR) | 0.96 (0.70–1.34) | 0.98 (0.69–1.33) | 0.94 (0.71–1.36) | 0.649 |
| Monocyte counta, median (IQR) | 0.39 (0.27–0.57) | 0.36 (0.25–0.54) | 0.45 (0.30–0.67) | <0.001* |
| Neutrophil counta, median (IQR) | 11.03 (8.17–13.81) | 10.20 (7.63–12.91) | 13.10 (10.02–16.19) | <0.001* |
| Platelet counta, median (IQR) | 228.50 (183.75–269.50) | 226.50 (181.00 −262.25) | 232.50 (195.25–292.25) | 0.028* |
| SIRI, median (IQR) | 4.24 (2.44–7.02) | 3.56 (2.25–5.77) | 6.17 (3.58–10.32) | <0.001* |
| MLR, median (IQR) | 0.26 (0.20–0.32) | 0.36 (0.26–0.51) | 0.47 (0.35–0.67) | <0.001* |
| PWR, median (IQR) | 18.36 (14.52–23.25) | 19.58 (15.76–23.47) | 15.98 (13.17–22.74) | 0.004* |
| PNR, median (IQR) | 21.17 (16.17–27.33) | 22.44 (17.50–28.40) | 17.95 (14.61–19.65) | 0.002* |
| NLR, median (IQR) | 11.52 (7.61–17.05) | 10.37 (6.12–15.72) | 13.60 (9.47–19.65) | 0.215 |
POP, postoperative pneumonia; mRS, modified Rankin scale; SD, standard deviation; IQR, interquartile range; WFNS, World Federation of Neurological Societies; mFS, modified Fisher Scale; SIRI, systemic inflammation response index; MLR, monocyte-to-lymphocyte ratio; PWR, platelet-to-white blood cell ratio; PNR, platelet-to-neutrophil ratio; NLR, neutrophil-to-lymphocyte ratio.
aUnit of measurement: 109/L.
*p <0.05.